Clinical Study Result:

After six months of treatment, the results showed a significant increase in the proportion of patients reporting a notable reduction in joint discomfort when they consumed Genacol AminoLock® Collagen compared to patients on placebo.

Bruyère O, et al. Effect of collagen hydrolysate in articular discomfort: A 6-month randomized, double-blind, placebo-controlled study. Complement Ther Med (2012).

The first study was a multicenter randomized placebo-controlled trial carried out in Belgium by world-renowned researchers(10).

Patients suffered from joint discomfort in various areas: upper body (shoulder, elbow, wrist), lower back or lower body (hip, knee).

Over 140 patients were randomly assigned to receive either 1200 mg of Genacol® AminoLock® Collagen or a placebo. The study was well balanced (baseline patient characteristics) and of excellent quality. The authors used a visual analog scale (VAS), the Gold Standard reference test, for the subjective assessment of discomfort. The VAS scale is notably used to demonstrate the clinical efficacy of analgesic drugs. It is recognized by regulatory agencies such as the US Federal Drug Agency (FDA) and the Canadian Therapeutic Products Directorate (TPD).

After six months of treatment, the clinical studies showed a significant increase in the proportion of responders (minimum 20% improvement in discomfort VAS score) compared to placebo.

This result is more significant if one considers that the study subjects suffered from discomfort in various joint areas. In contrast, most other trials concentrate on a particular joint (for example, the knee).

In fact, when results were segregated according to different body regions, treatment with Genacol’s AminoLock^® Collagen was even more impressive. For instance, for the upper body (shoulder, elbow, wrist) and the lower back, twice as many patients taking Genacol^® AminoLock^® Collagen noted an improvement in joint discomfort instead of patients on placebo.

Â